Laura Niklason (Humacyte)

Pi­o­neer­ing re­gen­er­a­tive med sci­en­tist Lau­ra Nikla­son takes her com­pa­ny pub­lic in the lat­est big SPAC deal. And that gives her a shot at mak­ing biotech his­to­ry

Lau­ra Nikla­son left a promi­nent po­si­tion at Yale last fall so she could take charge of her re­gen­er­a­tive med biotech at a crit­i­cal point in its 17-year his­to­ry.

Cel­e­brat­ed by Time and For­tune, her­ald­ed as a leader in the long-run­ning re­gen­er­a­tive med tech­nol­o­gy sto­ry in tis­sue en­gi­neer­ing, with roots in the field that go back to her days as a post­doc in Bob Langer’s sto­ried lab at MIT, the sci­en­tif­ic founder of Hu­ma­cyte made a ca­reer switch that put her in charge of a com­pa­ny with 130 staffers and on­go­ing late-stage pro­grams that could put them on the thresh­old of com­mer­cial­iza­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.